139 related articles for article (PubMed ID: 35347036)
1. Clinical Outcome and Prognostic Variables of Second-line Therapy for Patients With Castration-resistant Prostate Cancer After Failure of First-line Androgen Receptor Axis-targeted Therapy.
Fujiwara M; Fujiwara R; Oguchi T; Komai Y; Numao N; Yamamoto S; Yonese J; Yuasa T
Anticancer Res; 2022 Apr; 42(4):2123-2130. PubMed ID: 35347036
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer.
Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
Clin Genitourin Cancer; 2017 Dec; 15(6):e1073-e1080. PubMed ID: 28826931
[TBL] [Abstract][Full Text] [Related]
3. Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting.
Oh WK; Cheng WY; Miao R; Vekeman F; Gauthier-Loiselle M; Duh MS; Drea E; Szatrowski TP
Urol Oncol; 2018 Nov; 36(11):500.e1-500.e9. PubMed ID: 30201382
[TBL] [Abstract][Full Text] [Related]
4. Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up.
Kobayashi T; Terada N; Kimura T; Matsubara N; Murakami K; Mori K; Fujimoto Y; Akamatsu S; Inoue T; Ogawa O
Clin Genitourin Cancer; 2020 Feb; 18(1):e46-e54. PubMed ID: 31759831
[TBL] [Abstract][Full Text] [Related]
5. An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective.
Morgans AK; Hutson T; Guan AKD; Garcia D; Zhou A; Drea E; Vogelzang NJ
BMC Health Serv Res; 2022 Jul; 22(1):916. PubMed ID: 35836170
[TBL] [Abstract][Full Text] [Related]
6. The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study.
Naito Y; Kato M; Kawanishi H; Yuguchi Y; Yuba T; Ishikawa T; Hattori K; Yamamoto A; Sano T; Matsukawa Y; Kimura T; Nishikimi T; Hattori R; Tsuzuki T; Gotoh M
Prostate; 2020 Nov; 80(15):1373-1380. PubMed ID: 32914895
[TBL] [Abstract][Full Text] [Related]
7. Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents.
Hafron JM; Wilfehrt HM; Ferro C; Harmon M; Flanders SC; McKay RR
Adv Ther; 2022 Jun; 39(6):2515-2532. PubMed ID: 35352309
[TBL] [Abstract][Full Text] [Related]
8. Propensity score-matched comparison of docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant intraductal carcinoma of the prostate.
Yamamoto A; Kato M; Hattori K; Naito Y; Tochigi K; Sano T; Kawanishi H; Ishikawa T; Yuba T; Hattori R; Gotoh M; Tsuzuki T
BJU Int; 2020 May; 125(5):702-708. PubMed ID: 31833179
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan.
Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
Clin Genitourin Cancer; 2018 Jun; 16(3):219-225. PubMed ID: 29274813
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
Onal C; Kose F; Ozyigit G; Aksoy S; Oymak E; Muallaoglu S; Guler OC; Tilki B; Hurmuz P; Akyol F
Prostate; 2021 Jun; 81(9):543-552. PubMed ID: 33905131
[TBL] [Abstract][Full Text] [Related]
11. Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide.
Miyake H; Matsushita Y; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Med Oncol; 2017 Nov; 34(12):200. PubMed ID: 29164346
[TBL] [Abstract][Full Text] [Related]
12. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.
de Wit R; Wülfing C; Castellano D; Kramer G; Eymard JC; Sternberg CN; Fizazi K; Tombal B; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Foster MC; Ozatilgan A; Geffriaud-Ricouard C; de Bono J
ESMO Open; 2021 Oct; 6(5):100241. PubMed ID: 34450475
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer.
Shiota M; Blas L; Kobayashi S; Matsumoto T; Kashiwagi E; Takeuchi A; Inokuchi J; Shiga KI; Yokomizo A; Eto M
Int J Urol; 2022 Jan; 29(1):26-32. PubMed ID: 34549837
[TBL] [Abstract][Full Text] [Related]
14. No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer.
Miyake H; Matsushita Y; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Int J Clin Oncol; 2018 Jun; 23(3):576-583. PubMed ID: 29275450
[TBL] [Abstract][Full Text] [Related]
15. Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?
Pereira-Salgado A; Anton A; Franchini F; Mahar RK; Kwan EM; Wong S; Shapiro J; Weickhardt A; Azad AA; Spain L; Gunjur A; Torres J; Parente P; Parnis F; Goh J; Steer C; Brown S; Gibbs P; Tran B; IJzerman M
Expert Rev Pharmacoecon Outcomes Res; 2023 Feb; 23(2):231-239. PubMed ID: 36541133
[TBL] [Abstract][Full Text] [Related]
16. Prognosis and safety of radium-223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration-resistant prostate cancer: Real-world data of Japanese patients.
Miyoshi Y; Yasui M; Ttsutsumi S; Kawahara T; Uemura KI; Hayashi N; Nozawa M; Yoshimura K; Uemura H; Uemura H
BJUI Compass; 2021 Jan; 2(1):31-38. PubMed ID: 35474660
[TBL] [Abstract][Full Text] [Related]
17. Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer.
Mori K; Kimura T; Ito K; Onuma H; Tanaka M; Matsuura T; Kurokawa G; Iwatani K; Inaba Y; Sakanaka K; Sasaki H; Miki J; Shimomura T; Miki K; Egawa S
Prostate; 2018 Jul; 78(10):766-772. PubMed ID: 29635810
[TBL] [Abstract][Full Text] [Related]
18. Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD.
de Wit R; Freedland SJ; Oudard S; Marinov G; Capart P; Combest AJ; Peterson R; Ozatilgan A; Morgans AK
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):67-73. PubMed ID: 35039605
[TBL] [Abstract][Full Text] [Related]
19. Comparative Assessment of Efficacies Between 2 Alternative Therapeutic Sequences With Novel Androgen Receptor-Axis-Targeted Agents in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Miyake H; Hara T; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
Clin Genitourin Cancer; 2017 Aug; 15(4):e591-e597. PubMed ID: 28063845
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
